Non-cystic Fibrosis Bronchiectasis Drug Pipeline Market 2024 Featuring Zambon, AstraZeneca, Insmed, NovaBiotics, Haisco Pharmaceutical, Armata Pharmaceuticals, Chiesi Farmaceutici, & CSL B...
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
This "Non-cystic fibrosis bronchiectasis - Pipeline Insight, 2024" report provides comprehensive insights about 16+ companies and 17+ pipeline drugs in Non-cystic fibrosis bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-cystic fibrosis bronchiectasis pipeline landscape is provided which includes the disease overview and Non-cystic fibrosis bronchiectasis treatment guidelines. The assessment part of the report embraces, in depth Non-cystic fibrosis bronchiectasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the dru
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Evercore ISI from $42.00 to $75.00. They now have an "outperform" rating on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $72.00. They now have an "overweight" rating on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Mizuho from $36.00 to $82.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
INSM
Earnings
- 5/9/24 - Beat
INSM
Sec Filings
- 6/13/24 - Form 8-K
- 6/12/24 - Form 4
- 6/5/24 - Form 4
- INSM's page on the SEC website